Lascufloxacin

Lascufloxacin
Clinical data
Trade namesLasvic
Other namesKRP-AM1977
Identifiers
IUPAC name
  • 7-[(3S,4S)-3-[(Cyclopropylamino)methyl]-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC21H24F3N3O4
Molar mass439.435 g·mol−1
3D model (JSmol)
SMILES
  • COC1=C2C(=CC(=C1N3C[C@@H]([C@@H](C3)F)CNC4CC4)F)C(=O)C(=CN2CCF)C(=O)O

Lascufloxacin (trade name Lasvic) is an fluoroquinolone antibiotic drug for the treatment of bacterial infections. It has been approved since 2019 in Japan[1] to treat community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections.[2]

It has activity against various Gram-positive bacteria including Streptococcus pneumoniae[3] and Streptococcus anginosus.[4]

References

  1. ↑ "Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent Lasvic Tablets 75 mg" (PDF) (Press release). Kyorin Pharmaceutical Co. September 20, 2019. Retrieved July 3, 2021.
  2. ↑ "Lascufloxacin - Kyorin Pharmaceutical". Adis Insight. Retrieved July 3, 2021.
  3. ↑ Murata M, Kosai K, Yamauchi S, Sasaki D, Kaku N, Uno N, Morinaga Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K (April 2018). "In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions". Antimicrob Agents Chemother. 62 (4). doi:10.1128/AAC.01971-17. PMC 5913943. PMID 29439959.
  4. ↑ Yamagishi Y, Matsukawa Y, Suematsu H, Mikamo H (December 2018). "In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group". Anaerobe. 54: 61–64. doi:10.1016/j.anaerobe.2018.08.002. PMID 30114441.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.